Gilead Sciences

GILD · NASDAQ · USD

$144.74Change from previous close: −1.87%Absolute change: −$2.76

Close · October 2, 2026

At a glance

Revenue growth
+2.40%
2025 vs 2024
Net income growth
+1,672.92%
2025 vs 2024
Net margin
28.9%
2024: 1.7%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets49,36256,27859,02358,53355,72156,43458,99554,52553,57956,29262,12562,373
Current assets13,94518,64118,34217,87414,71816,90119,17314,77912,31714,04116,08515,980
Cash and equivalents3,1797,6287,5647,3305,1447,9269,9915,0372,7724,7186,0855,705
Short-term investments1,7032,1892,0491,1609147851,5771,6601,0098062,2652,269
Receivables5,0554,7414,9135,0954,7814,3884,4204,5874,6634,6694,6604,790
Inventory1,9531,9141,7741,7851,8251,7591,7101,8692,0261,8531,7871,663
Net property, plant and equipment5,8335,6386,1385,5005,4595,4215,9295,3915,3465,3215,8985,572
Goodwill8,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,314
Other intangible assets14,03216,38216,97817,97018,56619,35519,94820,54622,83223,42826,45427,152
Long-term investments7261,6703,7532,7782,6406847137307061,1441,8191,737
Current liabilities11,0209,47611,81312,29811,18912,34412,00411,72510,78113,01511,28011,945
Accounts payable674645715808582737833903537622550586
Long-term debt23,83220,86122,12922,13522,14022,14624,89621,43721,54021,52723,18923,189
Total debt26,24622,17424,93624,94124,946———————
Total liabilities37,61732,84736,40537,07736,13137,35639,74936,13435,38238,83739,37640,131
Total equity (incl. minority)11,74523,43122,61821,45619,59019,07819,24618,39118,19717,45522,74922,242
Retained earnings2,20014,13113,73012,82511,32510,93111,49711,07311,16510,65616,30416,002
Minority interest-84.0-84.0-84.0-84.0-84.0-84.0-84.0-84.0-84.0-84.0-84.0-72.0